Free Trial
NYSE:JNJ

Johnson & Johnson (JNJ) Stock Price, News & Analysis

$160.68
+0.99 (+0.62%)
(As of 10/9/2024 ET)

About Johnson & Johnson Stock (NYSE:JNJ)

Key Stats

Today's Range
$159.57
$161.22
50-Day Range
$157.85
$167.38
52-Week Range
$143.13
$168.85
Volume
6.05 million shs
Average Volume
7.06 million shs
Market Capitalization
$386.71 billion
P/E Ratio
10.02
Dividend Yield
3.09%
Price Target
$173.43
Consensus Rating
Hold

Company Overview

Johnson & Johnson is a US-based multinational pharmaceutical company that started in the early 1870s. Robert Wood Johnson began training as a pharmacist at 16 and founded his 1st company in 1873. That company would be disbanded by 1886 when Johnson joined his brothers to form today's entity. The company’s first line of products was sterile surgical dressings which were soon followed up by household products and medical guides.

Today, Johnson & Johnson is one of the world’s largest companies. It is ranked 36th on the 2021 Fortune 500 list and is a Dow Jones Industrial Average member. The company operates via 250 subsidiaries with operations in 60 countries and product sales in 175. As of 2021, annual sales were in the range of $95 billion and growing. The company is also a leader in equality and the advancement of women’s rights. Johnson & Johnson’s workforce was nearly 50% female by 1910, and many held significant positions of responsibility.

Among the company’s many advances in health care is the advancement of sterile conditions to prevent postoperative and secondary infections. Products include sterile gauze, cotton and dressings, and the development of the industrial sterilization process. However, the product that launched the company to success was the combination of a sterile dressing with tape. The company called the new products Band-Aids, which is now synonymous with small, prepackaged bandages. Another major win for the company was Johnson & Johnson Baby Soap.

Today, Johnson & Johnson operates in 3 segments: Pharmaceutical, Consumer Health and MedTech. The Consumer Health segment alone covers brands like Aveeno, Listerine, Tylenol, Zyrtec, Band-Aid and Neosporin, which are among the world’s most recognizable brands. The company’s purpose is to “blend science and ingenuity to change the trajectory of health for humanity profoundly”.

The Pharmaceutical segment offers products in all segments of the healthcare spectrum and has partnerships to develop new drugs with at least 10 other major healthcare providers and dozens of smaller research facilities. Products are offered wholesale to retailers and through healthcare systems. The MedTech segment develops and manufactures various healthcare devices and diagnostic tools. Among the many recognizable products from this segment are ACUVUE contact lenses.

Johnson & Johnson went public in 1944 and began paying dividends soon after. The company began increasing its dividend payment in 1962 and has increased it yearly. The company is a member of the Dividend Aristocrat Index and qualifies as a Dividend King with more than 50 years of consecutive annual increases. The company employs more than 142,000 individuals and serves more than 1 billion daily. Regarding the company’s health, its track record of dividend payments is backed up by a AAA credit rating. Johnson & Johnson is one of only 2 US corporations with such a rating and is more trusted than the US government.

The company announced plans to split into two publicly traded companies in 2021. The move is expected to be complete in late 2023 and will result in a Consumer Health company and a Pharmaceutical company.





Johnson & Johnson Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
94th Percentile Overall Score

JNJ MarketRank™: 

Johnson & Johnson scored higher than 94% of companies evaluated by MarketBeat, and ranked 76th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Johnson & Johnson has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 6 buy ratings, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Johnson & Johnson has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Johnson & Johnson's stock forecast and price target.
  • Earnings Growth

    Earnings for Johnson & Johnson are expected to grow by 5.99% in the coming year, from $10.02 to $10.62 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Johnson & Johnson is 10.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.36.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Johnson & Johnson is 10.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 133.20.

  • Price to Earnings Growth Ratio

    Johnson & Johnson has a PEG Ratio of 2.69. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Johnson & Johnson has a P/B Ratio of 5.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Johnson & Johnson's valuation and earnings.
  • Percentage of Shares Shorted

    0.96% of the float of Johnson & Johnson has been sold short.
  • Short Interest Ratio / Days to Cover

    Johnson & Johnson has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Johnson & Johnson has recently increased by 8.99%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Johnson & Johnson pays a meaningful dividend of 3.09%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Johnson & Johnson has been increasing its dividend for 63 years.

  • Dividend Coverage

    The dividend payout ratio of Johnson & Johnson is 30.92%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 46.70% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

  • Read more about Johnson & Johnson's dividend.
  • Percentage of Shares Shorted

    0.96% of the float of Johnson & Johnson has been sold short.
  • Short Interest Ratio / Days to Cover

    Johnson & Johnson has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Johnson & Johnson has recently increased by 8.99%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Johnson & Johnson has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 39 news articles for Johnson & Johnson this week, compared to 30 articles on an average week.
  • Search Interest

    Only 137 people have searched for JNJ on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.
  • MarketBeat Follows

    44 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is an increase of 63% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $930,113.00 in company stock.

  • Percentage Held by Insiders

    Only 0.16% of the stock of Johnson & Johnson is held by insiders.

  • Percentage Held by Institutions

    69.55% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Johnson & Johnson's insider trading history.
Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

JNJ Stock News Headlines

Security Symbol With Stacked Coins Over Grey Background — Photo
Top 3 Risk-Averse Stocks to Add Stability to Your Portfolio (JNJ)
Risk-averse investors can build a stable portfolio by focusing on established companies with consistent dividends and proven track records of success.
piece of pie dividend stock chart
3 Undervalued Dividend Stocks Primed for Growth in 2025 (JNJ)
These quality dividend stocks look significantly undervalued which gives you an opportunity to pair a high-yield dividend with strong capital appreciation
Ezekiel 7:23
Jim Rickards here - former advisor to the CIA, the White House, and the Pentagon - with an urgent warning regarding the 2024 election. I don’t want to frighten you. But as an American patriot, it is my Christian duty to share the illegal election plot I’ve just uncovered. See, the Kamala campaign may be planning something so egregious… so despicable… and frankly, so unconstitutional that it could completely destroy our country. I predict a 50% market crash… Violent riots in the streets… And the potential introduction of martial law.
Hand putting coin in jar word dividend with money stack, Concept business finance and investment.
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns (JNJ)
These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025.
Mikayla Brown and her husband, Tyler, visit the grave of their son, Elijah, who died of a fentanyl …
Dealers' paradise? How social media became a storefront for deadly fake pills as families struggle
Fentanyl overdoses have become a leading cause of death for minors in the last 5 years or so — and social media, where tainted, fake prescription drugs can be obtained with just a few clicks, is part of the problem
See More Headlines

JNJ Stock Analysis - Frequently Asked Questions

Johnson & Johnson's stock was trading at $156.74 on January 1st, 2024. Since then, JNJ stock has increased by 2.5% and is now trading at $160.65.
View the best growth stocks for 2024 here
.

Johnson & Johnson (NYSE:JNJ) announced its earnings results on Wednesday, July, 17th. The company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.71 by $0.11. The company's quarterly revenue was up 4.3% on a year-over-year basis.
Read the conference call transcript
.

Johnson & Johnson subsidiaries include these companies: Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and more.

Johnson & Johnson's top institutional shareholders include Handelsbanken Fonder AB (0.06%), Czech National Bank (0.02%), CWM LLC (0.02%) and AMF Tjanstepension AB (0.02%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Peter Fasolo, William Hait, Kathryn E Wengel, Ashley Mcevoy, Thibaut Mongon, Joseph J Wolk, Robert J Decker and James D Swanson.
View institutional ownership trends
.

Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
7/17/2024
Ex-Dividend for 9/10 Dividend
8/27/2024
Dividend Payable
9/10/2024
Today
10/09/2024
Next Earnings (Confirmed)
10/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
47816010
Employees
131,900
Year Founded
1886

Price Target and Rating

Average Stock Price Target
$173.43
High Stock Price Target
$215.00
Low Stock Price Target
$150.00
Potential Upside/Downside
+7.7%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

Net Income
$35.15 billion
Pretax Margin
22.53%

Debt

Sales & Book Value

Annual Sales
$86.58 billion
Cash Flow
$13.48 per share
Book Value
$28.57 per share

Miscellaneous

Outstanding Shares
2,406,679,000
Free Float
2,402,828,000
Market Cap
$387.45 billion
Optionable
Optionable
Beta
0.52

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NYSE:JNJ) was last updated on 10/9/2024 by MarketBeat.com Staff
From Our Partners